Immunome Shares Are Trading Higher After the Company Announced That It Entered Into a Definitive Asset Purchase Agreement With Ayala Pharmaceuticals to Acquire AL102 and AL101 Drug Candidates
Immunome宣佈與阿亞拉制藥公司簽訂最終資產購買協議以收購 AL102 和 AL101 候選藥物後，該公司股價走高